Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit www.RALLYStudy.com or www.clinicaltrials.gov (NCT04508621).
- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
Tonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit
Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering
Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)
